Ganciclovir 0.15% Eye Gel - TGA Unlicensed Products
HL Pharma has exclusive distribution rights for numerous products and also specialises in sourcing and supply of products that are unlicensed in Australia.
These products may not have TGA registration or may be Australian products with supply issues. They are usually supplied under The Special Access Scheme (SAS) or Authorised Prescriber Scheme (APS). Other pathways to supply include Clinical Trial Supply.
For more product information on Ganciclovir 0.15% Eye Gel and other brands including Virgan® see below. For further information on sourcing this product or any others, please don't hesitate to contact us.
Ganciclovir 0.15% Eye Gel
What is Ganciclovir 0.15% eye gel?
Ganciclovir eye gel is used for the treatment of acute herpetic keratitis (dendritic and geographic ulcers). It is licensed in the United Kingdom, Europe, Canada and USA. However, not licensed for use in Australia.
NLM Overview of Ganciclovir 0.15 % Eye Gel
The supply of unlicensed medicine from overseas in Australia is available under The Special Access Scheme.
What is Ganciclovir used for?
Ganciclovir 0.15% eye gel and other brands including Virgan®, are supplied under Special Access Scheme (SAS) A & B for the treatment of acute herpetic keratitis (dendritic and geographic ulcers).
The SAS A & B system requires the prescriber to notify The TGA of the use.
TGA Special Access Scheme & Authorised Prescriber summary
If a prescriber requires many patients to use Ganciclovir eye gel and other brands including Virgan® they can apply for an Authorised Prescriber approval.
HL Pharma is a specialist supplier of medicines from overseas. Please contact us for assistance and information.